Chimeric Antigen Receptor T-cell Therapies for Hematological Malignancies

CCR Grand Rounds James Kochenderfer, M.D., is a tenure-track investigator in the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI). For the past 12 years, Dr. Kochenderfer has focused on a full range of chimeric antigen receptor (CAR) research from designing and cons tructing new CARs to conducting clinical trials. Dr. Kochenderfer designed and constructed a novel anti-CD19 CAR and then participated in a clinical trial of this CAR. This clinical trial was the first to demonstrate antigen-specific activity of anti-CD19 CARs in humans. This work in anti-CD19 CAR T cells led to the first Food and Drug Administration-approved CAR T-cell therapy for lymphoma. Dr. Kochenderfer designed the first chimeric antigen receptor targeting B-cell maturation antigen (BCMA). He then led the first clinical trial of T cells expressing an anti-BCMA CAR as a treatment for mul tiple myeloma. Dr. Kochenderfer is currently principle investigator of CAR T-cell clinical trials targeting lymphoma, leukemia, and multiple myeloma. He also leads a lab that designs new CARs and studies CAR T-cell biology. Dr. Kochenderfer received his M.D. from West Virginia University and then co mpleted training in internal medicine at Vanderbilt University, a medical oncology fellowship at the M.D. Anderson Cancer Center, and a hematology fellowship at Baylor College of Medicine, followed by postdoctoral research training in T-cell immunotherapy at the National Cancer Ins...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video